2021-08-06 GP (HK) Enters into Strategic Cooperation with CoRISMA on Equity Interests and Products, Introducing a Global Innovative Advanced Heart Failure Therapeutic System

2021-08-02 GP (HK) Enters into Investment and Strategic Cooperation Agreements with FastWave

2021-07-27 GP (HK) Announces the Positive Profit Alert, The Consolidated Net Profit Attributable to Owners of the Company for the First Half of 2021 is Expected to Increase Not Less Than 50%

2021-07-08 P (HK)’s Associate OncoSec Enters into A Collaboration Agreement with Merck to Conduct a Global Phase III Study in Advanced Metastatic Melanoma.

2021-07-08 GP(HK) Global Innovative RDC TLX250-CDX Dosed the First Patient with the Expanding Indication in Australia

2021-07-02 GP (HK) Subscribes for New Shares of Sirtex HoldCo and Reaches the TRS Agreements with Natixis.

2021-06-04 GP (HK)’s Two Global Innovative RDC Products Usher in a New Breakthrough, TLX591-CDx Dosed the First Patient in Japan;

2021-06-03 GP (HK) Obtains Exclusive Development and Commercialization Rights of Improved New Drug for Anti-inflammatory and Pain Relief after Ophthalmology Surgery

2021-06-01 GP (HK) Appoints Mr. Zhou Chao as CEO

2021-05-30 GP (HK) Exclusively Introduces Global Innovative Breakthrough Medical Device The New Generation Heartlight X3 Laser Ablation Platform from Cardiofocus

2021-05-26 GP (HK) Acquires Shenming Medical Technology Co., Ltd. Obtains All Rights of an Innovative Thermosensitive Embolic Agent for the Treatment of Liver Cancer. Further Expands the Tumor Intervention Treatment Product Pipeline

2021-05-24 GP (HK)’s Global Innovation Product STC3141 Enrolled and Dosed Four Patients for the Phase IIa Clinical Trial of Covid-19 in Belgium Rapidly Advance the Global Development Process